Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 548-560

  Khatri, Alpa ^a   Burger, Pieter B ^a   Swanger, Sharon A ^a   Hansen, Kasper B ^b   Zimmerman, Sommer ^a   Karakas, Erkan ^c   Liotta, Dennis C ^a   Furukawa, Hiro ^c   Snyder, James P ^a   Traynelis, Stephen F ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE TRANSPORTER; GLUTAMIC ACID; GLYCINE; KAINIC ACID; KAPPA OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PYD 106; SEROTONIN 3A RECEPTOR; UNCLASSIFIED DRUG; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NR2C NMDA RECEPTOR;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DISSOCIATION CONSTANT; EC50; EFFECTIVE CONCENTRATION; EMBRYO; HEK293 CELL LINE; HILL COEFFICIENT; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MUTAGENESIS; OUTSIDE OUT PATCH CLAMP; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; ANIMAL; CELL LINE; METABOLISM; PHYSIOLOGY; RAT; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CELL LINE; GLUTAMIC ACID; GLYCINE; HEK293 CELLS; HUMANS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 84911030523     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094516     Document Type: Article

References (84)

1. Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger PB, Mullasseril P, Snyder JP, and Liotta DC et al. (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol 80:782-795.
2. Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, and Mizuno N (1994) Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 347:150-160.
3. Balu DT and Coyle JT (2011) Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 35:848-870.
4. Bettini E, Sava A, Griffante C, Carignani C, Buson A, Capelli AM, Negri M, Andreetta F, Senar-Sancho SA, and Guiral L et al. (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J Pharmacol Exp Ther 335:636-644.
5. Binshtok AM, Fleidervish IA, Sprengel R, and Gutnick MJ (2006) NMDA receptors in layer 4 spiny stellate cells of the mouse barrel cortex contain the NR2C subunit. J Neurosci 26:708-715.
6. Cathala L, Misra C, and Cull-Candy S (2000) Developmental profile of the changing properties of NMDA receptors at cerebellar mossy fiber-granule cell synapses. J Neurosci 20:5899-5905.
7. Chazot PL, Coleman SK, Cik M, and Stephenson FA (1994) Molecular characterization of N-methyl-D-aspartate receptors expressed in mammalian cells yields evidence for the coexistence of three subunit types within a discrete receptor molecule. J Biol Chem 269:24403-24409.
8. Chen PE, Geballe MT, Katz E, Erreger K, Livesey MR, O'Toole KK, Le P, Lee CJ, Snyder JP, and Traynelis SF et al. (2008) Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol 586:227-245.
9. Clarke RJ and Johnson JW (2006) NMDA receptor NR2 subunit dependence of the slow component of magnesium unblock. J Neurosci 26:5825-5834.
10. Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, and Costa BM et al. (2013) The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 64:13-26.
11. Colquhoun D, Sigworth F (1995). Fitting In: Sakmann B, Neher E (eds). Single-channel Recordings, edn. New York, NY: Plenum Press. pp 483-587.
12. Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Laube B, Jane DE, and Monaghan DT (2012) Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. Neuropharmacology 62:1730-1736.
13. Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, and Monaghan DT (2010) A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther 335:614-621.
14. Dravid SM, Burger PB, Prakash A, Geballe MT, Yadav R, Le P, Vellano K, Snyder JP, and Traynelis SF (2010) Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci 30:2741-2754.
15. Edgar RC (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5:113 DOI: 10.1186/1471-2105-5-113.
16. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, Milh M, Kortüm F, Fritsch A, and Pientka FK et al. (2010) Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42:1021-1026.
17. Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, and Micale N et al. (2007) Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol 72:907-920.
18. Erreger K and Traynelis SF (2005) Allosteric interaction between zinc and glutamate binding domains on NR2A causes desensitization of NMDA receptors. J Physiol 569:381-393.
19. Farrant M, Feldmeyer D, Takahashi T, and Cull-Candy SG (1994) NMDA-receptor channel diversity in the developing cerebellum. Nature 368:335-339.
20. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, and Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196.
21. Gielen M, Siegler Retchless B, Mony L, Johnson JW, and Paoletti P (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459:703-707.
22. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, and Green MF (2008) Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 106:320-327.
23. Goff DC, Tsai G, Manoach DS, and Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
24. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, and Goff DC (2011) D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 131:69-74.
25. Hallett PJ and Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155-174.
26. Hansen KB, Furukawa H, and Traynelis SF (2010) Control of assembly and function of glutamate receptors by the amino-terminal domain. Mol Pharmacol 78:535-549.
27. Hansen KB, Ogden KK, and Traynelis SF (2012) Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci 32:6197-6208.
28. Hansen KB, Ogden KK, Yuan H, and Traynelis SF (2014) Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron 81:1084-1096.
29. Hansen KB, Tajima N, Risgaard R, Perszyk RE, Jørgensen L, Vance KM, Ogden KK, Clausen RP, Furukawa H, and Traynelis SF (2013) Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors. Mol Pharmacol 84:114-127.
30. Hansen KB and Traynelis SF (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci 31:3650-3661.
31. Hatton CJ and Paoletti P (2005) Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 46:261-274.
32. Hillman BG, Gupta SC, Stairs DJ, Buonanno A, and Dravid SM (2011) Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem 95:404-414.
33. Hollmann M, Boulter J, Maron C, Beasley L, Sullivan J, Pecht G, and Heinemann S (1993) Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron 10:943-954.
34. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, and Masu M et al. (1993) Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem 268:2836-2843.
35. Jang MK, Mierke DF, Russek SJ, and Farb DH (2004) A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. Proc Natl Acad Sci USA 101:8198-8203.
36. Kalia LV, Kalia SK, and Salter MW (2008) NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 7:742-755.
37. Kaplan GB and Moore KA (2011) The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 99:217-228.
38. Káradóttir R, Cavelier P, Bergersen LH, and Attwell D (2005) NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438:1162-1166.
39. Karakas E and Furukawa H (2014) Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 344:992-997.
40. Karavanova I, Vasudevan K, Cheng J, and Buonanno A (2007) Novel regional and developmental NMDA receptor expression patterns uncovered in NR2C subunit-beta-galactosidase knock-in mice. Mol Cell Neurosci 34:468-480.
41. Kostakis E, Jang MK, Russek SJ, Gibbs TT, and Farb DH (2011) A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons. J Neurochem 119:486-496.
42. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
43. Laube B, Hirai H, Sturgess M, Betz H, and Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18:493-503.
44. Laurie DJ, Putzke J, Zieglgänsberger W, Seeburg PH, and Tölle TR (1995) The distribution of splice variants of the NMDAR1 subunit mRNA in adult rat brain. Brain Res Mol Brain Res 32:94-108.
45. Laurie DJ and Seeburg PH (1994) Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J Neurosci 14:3180-3194.
46. Lee CH, Lü W, Michel JC, Goehring A, Du J, Song X, and Gouaux E (2014) NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 511:191-197.
47. Lisman J (2012) Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Curr Opin Neurobiol 22:537-544.
48. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, and Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
49. Lu C, Fu Z, Karavanov I, Yasuda RP, Wolfe BB, Buonanno A, and Vicini S (2006) NMDA receptor subtypes at autaptic synapses of cerebellar granule neurons. J Neurophysiol 96:2282-2294.
50. Malayev A, Gibbs TT, and Farb DH (2002) Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol 135:901-909.
51. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, Yin X, Trapp BD, McRory JE, and Rehak R et al. (2006) NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439:988-992.
52. Monaghan DT, Irvine MW, Costa BM, Fang G, and Jane DE (2012) Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int 61:581-592.
53. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
54. Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Bräuner-Osborne H, Liotta DC, and Traynelis SF (2010) Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. J Med Chem 53:5476-5490.
55. Mott DD, Erreger K, Banke TG, and Traynelis SF (2001) Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy. J Physiol 535:427-443.
56. Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, Santangelo R, Orr AG, Le P, and Vellano KM et al. (2010) A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun 1:90 DOI: 10.1038/ncomms1085.
57. Norberg MM, Krystal JH, and Tolin DF (2008) A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 63:1118-1126.
58. Ogden KK and Traynelis SF (2011) New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 32:726-733.
59. Ogden KK and Traynelis SF (2013) Contribution of the M1 transmembrane helix and pre-M1 region to positive allosteric modulation and gating of N-methyl-D-aspartate receptors. Mol Pharmacol 83:1045-1056.
60. Olney JW, Newcomer JW, and Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
61. Petrovic M, Sedlacek M, Horak M, Chodounska H, and Vyklický L, Jr (2005) 20-oxo-5beta-pregnan-3alpha-yl sulfate is a use-dependent NMDA receptor inhibitor. J Neurosci 25:8439-8450.
62. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, and Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637.
63. Prybylowski K, Rumbaugh G, Wolfe BB, and Vicini S (2000) Increased exon 5 expression alters extrasynaptic NMDA receptors in cerebellar neurons. J Neurochem 75:1140-1146.
64. Qian A, Buller AL, and Johnson JW (2005) NR2 subunit-dependence of NMDA receptor channel block by external Mg21. J Physiol 562:319-331.
65. Rumbaugh G, Prybylowski K, Wang JF, and Vicini S (2000) Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J Neurophysiol 83:1300-1306.
66. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
67. Salter MG and Fern R (2005) NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167-1171.
68. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, and Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221-234.
69. Sheinin A, Shavit S, and Benveniste M (2001) Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41:151-158.
70. Siegler Retchless B, Gao W, and Johnson JW (2012). A single GluN2 subunit residue controls NMDA receptor channel properties via intersubunit interaction. Nat Neurosci 15: 406-413, S1-2.
71. Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, Stairs DJ, and Dravid SM (2014). GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol 171(3):799-809.
72. Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, and Powers JL (1998) Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18:6163-6175.
73. Traynelis SF, Hartley M, and Heinemann SF (1995) Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 268:873-876.
74. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496.
75. Ulbrich MH and Isacoff EY (2007) Subunit counting in membrane-bound proteins. Nat Methods 4:319-321.
76. Vance KM, Hansen KB, and Traynelis SF (2012) GluN1 splice variant control of GluN1/GluN2D NMDA receptors. J Physiol 590:3857-3875.
77. Vance KM, Simorowski N, Traynelis SF, and Furukawa H (2011) Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun 2:294 DOI: 10.1038/ncomms1295.
78. Watanabe M, Inoue Y, Sakimura K, and Mishina M (1992) Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3:1138-1140.
79. Wenzel A, Fritschy JM, Mohler H, and Benke D (1997) NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 68:469-478.
80. Williams K, Russell SL, Shen YM, and Molinoff PB (1993) Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 10:267-278.
81. Wu LJ and Zhuo M (2009) Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 6:693-702.
82. Yuan H, Hansen KB, Vance KM, Ogden KK, and Traynelis SF (2009) Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci 29:12045-12058.
83. Zhu S, Stroebel D, Yao CA, Taly A, and Paoletti P (2013) Allosteric signaling and dynamics of the clamshell-like NMDA receptor GluN1 N-terminal domain. Nat Struct Mol Biol 20:477-485.
84. Zimmerman SS, Khatri A, Garnier-Amblard EC, Mullasseril P, Kurtkaya NL, Gyoneva S, Hansen KB, Traynelis SF, and Liotta DC (2014) Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators. J Med Chem 57:2334-2356.